JK Cement, ICICI Lombard, CDSL among 4 stock picks by SMC Global for decent gains
SMC Global believes that JK Cement is strategically positioned to benefit from India’s infrastructure and housing boom, with a strong presence in high-growth North and Central markets.
- Apr 28, 2025,
- Updated Apr 28, 2025 9:35 AM IST
Amid the rising volatility in the Indian stock markets, domestic brokerage firm SMC Global Securities has suggested four stocks- ICICI Lombard General Insurance, Central Depository Services (India), JK Cement and Medplus Health Services - to bet amid the scarce opportunities to make money. The brokerage has picked the former two based on their strong technical charts, while the latter two appear to be robust based on their sound fundamentals. Here's what the brokerage has to say about these counters:
Medplus Health is in the business of pathological laboratory testing and manufacturing, wholesale trading and contract manufacturing of pharma, fast-moving consumer goods and beauty products and rendering of management services to group companies and holds investments in subsidiary companies. It operates in 13 states and continues to expand its store network while optimizing existing operations. The management anticipates sustainedGMV growth aligned with the pharma market, driven by inflation and market trends, despite a slight branded pharma slowdown due to rising private label sales and seasonality. It aims to maintain 10-11 per cent store-level EBITDA margins while managing new store cannibalization. With plans for 600 annual store additions and enhanced operational efficiency via new warehouses, management is optimistic about achieving robust growth and operational stability. Thus, it is expected that the stock may see a price target of Rs 933 in 8 to 10 months
Amid the rising volatility in the Indian stock markets, domestic brokerage firm SMC Global Securities has suggested four stocks- ICICI Lombard General Insurance, Central Depository Services (India), JK Cement and Medplus Health Services - to bet amid the scarce opportunities to make money. The brokerage has picked the former two based on their strong technical charts, while the latter two appear to be robust based on their sound fundamentals. Here's what the brokerage has to say about these counters:
Medplus Health is in the business of pathological laboratory testing and manufacturing, wholesale trading and contract manufacturing of pharma, fast-moving consumer goods and beauty products and rendering of management services to group companies and holds investments in subsidiary companies. It operates in 13 states and continues to expand its store network while optimizing existing operations. The management anticipates sustainedGMV growth aligned with the pharma market, driven by inflation and market trends, despite a slight branded pharma slowdown due to rising private label sales and seasonality. It aims to maintain 10-11 per cent store-level EBITDA margins while managing new store cannibalization. With plans for 600 annual store additions and enhanced operational efficiency via new warehouses, management is optimistic about achieving robust growth and operational stability. Thus, it is expected that the stock may see a price target of Rs 933 in 8 to 10 months